BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 23, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 25, 2021

View Archived Issues
Fluxergy products

Fluxergy corrals CE mark for 1-hour COVID-19 test

Fluxergy Inc. said Thursday that it has won CE-IVD marking for its one-hour COVID-19 real-time polymerase chain reaction (RT-PCR) test. The automated, sample-to-action Fluxergy diagnostic testing system can run multiple assay types – such as molecular, immunochemistry, chemistry and cytometry – simultaneously on the same cartridge. The SARS-CoV2 RT-PCR test is the first CE-marked product for the Fluxergy diagnostic platform. Read More
FDA-icons

FDA recommends vision check before applying dermal fillers

The use of dermal fillers has spiked in recent years for a number of reasons, but so have the associated adverse events. An FDA advisory committee made several associated recommendations, including that a patient’s vision be prospectively evaluated prior to any peri-ocular treatment with fillers, but this could be a simple count-the-fingers check, something that should not appreciably increase procedure times or affect the volume of procedures. Read More
Product image closeup

Vetex Revene study demonstrates positive results in 100% of thrombectomy patients

Vetex Medical Ltd.'s Revene thrombectomy catheter reduced symptoms and improved quality of life in all patients with iliofemoral vein thrombus in a European clinical study. The results were presented at Venous 2021, the annual meeting of the American Venous Forum. Read More
Cancer-and-Cancer-immunotherapy.png

Genetron’s blood-based HCC test shows promising results vs. the standard of care

Genetron Holdings Ltd. said its blood-based, early screening test for hepatocellular carcinoma (HCC) demonstrated 88% sensitivity and 93% specificity in 1,615 subjects in China vs. 71% sensitivity and 95% specificity with the use of ultrasound plus alpha-fetoprotein (AFP). The primary outcome, unveiled on March 25, came from a multicenter prospective trial that Beijing-based Genetron initiated together with The National Cancer Center China in 2019. Read More
Jazz implants on spine

Implanet acquires OSD to create a new benchmark player in orthopedic surgery

PARIS – Implanet SA won approval from its founding shareholders to acquire a majority stake in spinal implant manufacturer Orthopaedic & Spine Development SAS (OSD). Implanet’s bid is aimed at acquiring majority control, and potentially the entire share capital, of Avignon, France-based OSD, valued at $5 million. OSD’s founding shareholders, representing 71.5% of the capital, have already committed to respond favorably to the bid, thus confirming the principles behind this merger. Read More

Financings for March 25, 2021

Med-tech firms raising money in public or private financings, including: Better Health, Healum, Lightpoint Medical, Nuclein. Read More

In the clinic for March 25, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Boston Scientific, Genetron, Tethis. Read More

Other news to note for March 25, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adhererx, Biostem Technologies, Broad Institute, Cochrane, Congenica, Deep Lens, Dropprint Genomics, Emed, Genmark Diagnostics, Health Logic Interactive, Hitachi, Immunai, Intervalve Medical, Isotopia Medical Imaging, Keystone Heart, Kyowa Kirin Pharmaceutical Research, Mobileodt, Molecular Targeting Technologies, Movendo Technology, Optimus Health Services, PCR Oncology, Roche, Smith+Nephew, Sanford Health, Sophia Genetics, Thermo Fisher Scientific, Twist Bioscience X.labs. Read More

Regulatory actions for March 25, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aurora Spine, Fluxergy, Rapid Medical, Tiger Tech. Read More

Regulatory front for March 25, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: FDA seeks nominations for blood products advisory panel; Massachusetts hospital hit for HIPAA access non-compliance; No reports recorded for Medtronic recall; Tillis, Cotton eye patent examiner practice for Section 101 problem. Read More

BioWorld MedTech’s Diagnostics Extra for March 25, 2021

Keeping you up to date on recent developments in diagnostics, including: Review highlights differences in accuracy of COVID-19 rapid tests; Likelihood of disease from hidden genetic defects; Confocal PET enables color differentiation of PET tracers in preclinical imaging. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

    BioWorld Science
    At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing